INK 128 (MLN0128) 化学構造
分子量: 309.33



Quality Control & MSDS


  • Compare mTOR Inhibitors
  • 研究分野
  • Combination Therapy



製品説明 INK 128 (MLN0128)は、有力で選択的なmTOR 阻害剤で、 IC50 が 1 nMです。
ターゲット mTOR
IC50 1 nM [1]
In vitro試験 INK 128 exhibits an enzymatic inhibition activity against mTOR and more than 100-fold selectivity to PI3K kinases. [1] As TORC1/2 inhibitor, INK 128 inhibits both the phosphorylation of S6 and 4EBP1, the downstream substrates of TORC1, and selectively inhibits AKT phosphorylation at Ser473, the downstream substrate of TORC2. Furthermore, INK 128 also shows potent inhibition effects on cell lines resistant to rapamycin and pan-PI3K inhibitors. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
PANC-1  MlG0R4VtdCCYaXHibYxqfHliQYPzZZk> MUCxMVExOCCwTR?= NX\POnVxPzJiaB?= NX;E[XBncW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MXqyOFk4OTV2NB?=
PANC-1  NGq1WpVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWm1NEBvVQ>? NF;YZmMzPC17NjDo M1jITolvcGmkaYTzJINmdGxidnnhZoltcXS7IITpcYUh\GWyZX7k[Y51dHl? NUnTZXFCOjR7N{G1OFQ>
MIA PaCa-2 NH3yUpJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGLQO|UyNTFyMDDuUS=> MkTJO|IhcA>? NEfBNmNqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MX6yOFk4OTV2NB?=
PANC-1  MmDnRZBweHSxc3nzJGF{e2G7 NVfkcoVwOTBvMUCwJI5O NGHJRpk4OiCq MljCbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= NFTBdlczPDl5MUW0OC=>
PANC-1  MmfJSpVv[3Srb36gRZN{[Xl? NVjoT3dqOTBxNUCgcm0> MUWyOEBp NVLtdWp5\HKjbXH0bYNidGy7IHnubIljcXS|IIDoc5NxcG:{eXzheIlwdiCxZjC0SU1DWDFvU{\LNUApdVSRUlOxJIFkfGm4YYTpc44hcW6maXPheI9zeyliYX7kJGFsfCCjdDDT[ZIhPDd|IDj0bIUhdVSRUlOyJIFkfGm4YYTpc44hcW6maXPheI9zMQ>? MXiyOFk4OTV2NB?=
PANC-1  NXXTRZBvTnWwY4Tpc44hSXO|YYm= MnrsOVAhdk1? MUC0PEBp NUDNb3Bw\Gm|coXweJMh[2WubDDjfYNt\SCycn;ndoV{e2mxbh?= NGDtbnMzPDl5MUW0OC=>
PANC-1  MoXuSpVv[3Srb36gRZN{[Xl? MV[xNEBvVQ>? MmPSO|IhcA>? MXzpcoNz\WG|ZYOg[4Vu[2m2YXLpcoUhe2Wwc3n0bZZqfHl? NX\0ZZMyOjR7N{G1OFQ>

... Click to View More Cell Line Experimental Data

In vivo試験 In a ZR-75-1 breast cancer xenograft model, INK 128 shows tumor growth inhibition efficacy at a dose of 0.3 mg/kg/day. [1] Daily, oral administration of INK 128 inhibits angiogenesis and tumor growth in multiplexenograft models. [2]
臨床試験 INK 128 is currently in Phase I clinical trials in patients with relapsed or refractory multiple myeloma or waldenstrom macroglobulinemia.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download INK 128 (MLN0128) SDF
分子量 309.33


CAS No. 1224844-38-5
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 62 mg/mL (200.43 mM)
エタノール 2 mg/mL (6.46 mM)
<1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 3-(2-aminobenzo[d]oxazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

文献中の引用 (7)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021(CT99021)は、GSK-3αとGSK-3β阻害剤で、IC50 がそれぞれ 10 nM と 6.7 nMである。

  • Dorsomorphin (Compound C, BML-275)

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。

  • Everolimus (RAD001)

    Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。

  • AZD8055


    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin1は、mTORの強力な阻害剤で、IC50 が 2-10 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。


Tags: INK 128 (MLN0128)を買う | INK 128 (MLN0128)供給者 | INK 128 (MLN0128)を購入する | INK 128 (MLN0128)費用 | INK 128 (MLN0128)生産者 | オーダーINK 128 (MLN0128) | INK 128 (MLN0128)代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID